A phase I study of HER1, HER2 dual kinase inhibitor lapatinib plus the proteasome inhibitor bortezomib in patients with advanced malignancies

[1]  M. Burkard,et al.  Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer , 2016, Clinical Cancer Research.

[2]  J. Marshall,et al.  A phase 1 study of cetuximab and lapatinib in patients with advanced solid tumor malignancies , 2015, Cancer.

[3]  A. Iasonos,et al.  Predictors of early treatment discontinuation in patients enrolled on Phase I oncology trials , 2015, Oncotarget.

[4]  Chia-Hung Chen,et al.  Lapatinib–induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors , 2013, BMC Genomics.

[5]  夏德椿,et al.  Lapatinib-induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors , 2013 .

[6]  J. Gustafsson,et al.  Lapatinib induces p27Kip1-dependent G₁ arrest through both transcriptional and post-translational mechanisms , 2013, Cell cycle.

[7]  M. Tomita,et al.  Temporal Profiling of Lapatinib-suppressed Phosphorylation Signals in EGFR/HER2 Pathways* , 2012, Molecular & Cellular Proteomics.

[8]  J. Bondaruk,et al.  Low molecular weight cyclin E is associated with p27-resistant, high-grade, high-stage and invasive bladder cancer , 2012, Cell cycle.

[9]  Henk-Jan Guchelaar,et al.  Lapatinib for advanced or metastatic breast cancer. , 2012, The oncologist.

[10]  E. Petricoin,et al.  One-Step Preservation of Phosphoproteins and Tissue Morphology at Room Temperature for Diagnostic and Research Specimens , 2011, PloS one.

[11]  E. Vokes,et al.  Randomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small-cell lung cancer and a performance status of 2: CALGB 30402. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Michael J. Emanuele,et al.  A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene , 2009, Cell.

[13]  R. Kratzke,et al.  Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor , 2009, British Journal of Cancer.

[14]  D. Piwnica-Worms,et al.  Proteasome inhibition blocks ligand-induced dynamic processing and internalization of epidermal growth factor receptor via altered receptor ubiquitination and phosphorylation. , 2009, Cancer research.

[15]  F. Ciardiello,et al.  Synergistic anti‐proliferative and pro‐apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti‐epidermal growth factor receptor (EGFR) drugs in human cancer cells , 2008, Journal of cellular physiology.

[16]  Fang Wang,et al.  Proteasome Inhibition Activates Epidermal Growth Factor Receptor (EGFR) and EGFR-Independent Mitogenic Kinase Signaling Pathways in Pancreatic Cancer Cells , 2008, Clinical Cancer Research.

[17]  G. Hortobagyi,et al.  Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells , 2008, Molecular Cancer Therapeutics.

[18]  J. Lorch,et al.  Bortezomib inhibits cell-cell adhesion and cell migration and enhances epidermal growth factor receptor inhibitor-induced cell death in squamous cell cancer. , 2007, Cancer research.

[19]  M. Rettig,et al.  Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib , 2007, Molecular Cancer Therapeutics.

[20]  J. Marshall.  Clinical implications of the mechanism of epidermal growth factor receptor inhibitors , 2006, Cancer.

[21]  J. Adams.  The proteasome: a suitable antineoplastic target , 2004, Nature Reviews Cancer.

[22]  E. Raymond,et al.  [Epidermal growth factor inhibitors]. , 2003, La Revue de medecine interne.